First Reported Advanced Pancreatic Cancer With Hyperprogression Treated With PD-1 Blockade combined with chemotherapy: A Case Report And Literature Review

First Reported Advanced Pancreatic Cancer With Hyperprogression Treated With PD-1 Blockade combined with chemotherapy: A Case Report And Literature Review | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Case Report First Reported Advanced Pancreatic Cancer With Hyperprogression Treated With PD-1 Blockade combined with chemotherapy: A Case Report And Literature Review Ya-Zhou Wang, Mao-Zhen Peng, Yao-Lin Xu, Ying Ying, Lin-Hui Tang, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4673771/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 9 You are reading this latest preprint version Abstract Immunotherapy has demonstrated significant potential in the treatment of cancer and is now recommended as a first-line therapy for small cell lung cancer and melanoma. However, a novel response pattern has been delineated, characterized by an abrupt acceleration of tumor growth subsequent to immunotherapy. These unforeseen adverse events are denoted as hyper progressive disease (HPD). The occurrence of HPD is observed not only in patients undergoing immunotherapy but also in those receiving chemotherapy, albeit with a comparatively lower frequency within the chemotherapy cohort. In the management of metastatic pancreatic cancer, the combination of chemotherapy and immunotherapy presents a promising therapeutic approach; however, there remains an unresolved question regarding the association between this combination therapy and HPD. Herein, we present a case report of a 59-year-old patient with metastatic pancreatic cancer exhibiting high PD-1/PD-L1 expression identified through next-generation sequencing data, suggesting the potential efficacy of PD-1 immunotherapy. Therefore, we administered serplulimab (a novel anti-PD-1 antibody) in combination with gemcitabine/nab-paclitaxel. The patient initially exhibited a favorable response to the combination therapy of immunotherapy and chemotherapy; however, subsequent tumor enlargement and a significant deterioration in physical condition occurred. To our knowledge, this is the first reported case of HPD in pancreatic cancer with multiple metastases treated using combination therapy. Based on this case, we propose a potential association between combination therapy and HPD in pancreatic cancer. Pancreatic cancer combination therapy MDM4 amplification hyperprogressive disease case report Full Text Additional Declarations No competing interests reported. Supplementary Files Supplementaryexcelsheet1.xlsx Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Revision requested 30 Jul, 2024 Reviews received at journal 28 Jul, 2024 Reviews received at journal 27 Jul, 2024 Reviewers agreed at journal 27 Jul, 2024 Reviewers agreed at journal 27 Jul, 2024 Reviewers invited by journal 15 Jul, 2024 Editor assigned by journal 15 Jul, 2024 Submission checks completed at journal 13 Jul, 2024 First submitted to journal 02 Jul, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4673771","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Case Report","associatedPublications":[],"authors":[{"id":333697520,"identity":"7f131dec-1ff5-45bb-b6a5-9609cf8e7394","order_by":0,"name":"Ya-Zhou Wang","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"prefix":"","firstName":"Ya-Zhou","middleName":"","lastName":"Wang","suffix":""},{"id":333697521,"identity":"20735f23-2661-4488-92f3-b85fe48e00c4","order_by":1,"name":"Mao-Zhen Peng","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"prefix":"","firstName":"Mao-Zhen","middleName":"","lastName":"Peng","suffix":""},{"id":333697522,"identity":"69500357-e127-492f-87ad-49883a21f898","order_by":2,"name":"Yao-Lin Xu","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"prefix":"","firstName":"Yao-Lin","middleName":"","lastName":"Xu","suffix":""},{"id":333697523,"identity":"0b90b3b8-4987-4f6f-b712-aa508d162191","order_by":3,"name":"Ying Ying","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"prefix":"","firstName":"Ying","middleName":"","lastName":"Ying","suffix":""},{"id":333697525,"identity":"eb6b091b-6b61-4701-b8a5-95f744fe62b9","order_by":4,"name":"Lin-Hui Tang","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"prefix":"","firstName":"Lin-Hui","middleName":"","lastName":"Tang","suffix":""},{"id":333697526,"identity":"b5c409ca-d72a-4a79-934d-60698536352b","order_by":5,"name":"Hua-Xiang Xu","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"prefix":"","firstName":"Hua-Xiang","middleName":"","lastName":"Xu","suffix":""},{"id":333697527,"identity":"0e5f804f-d882-4b15-96b7-948298e7b921","order_by":6,"name":"Jun-Yi He","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"prefix":"","firstName":"Jun-Yi","middleName":"","lastName":"He","suffix":""},{"id":333697530,"identity":"1a03ab04-5d55-440f-82b1-44c330029981","order_by":7,"name":"Liang Liu","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"prefix":"","firstName":"Liang","middleName":"","lastName":"Liu","suffix":""},{"id":333697532,"identity":"66098d36-307e-4d03-84a7-98b7b093aa88","order_by":8,"name":"Wen-Quan Wang","email":"data:image/png;base64,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","orcid":"","institution":"Fudan University","correspondingAuthor":true,"prefix":"","firstName":"Wen-Quan","middleName":"","lastName":"Wang","suffix":""}],"badges":[],"createdAt":"2024-07-02 11:15:11","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4673771/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4673771/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":61888282,"identity":"e65b7f26-b4b0-4140-8dea-8de9dfe27750","added_by":"auto","created_at":"2024-08-06 17:25:59","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":613906,"visible":true,"origin":"","legend":"","description":"","filename":"MSPancreaticcancerwithHPDtreatedwithICB.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4673771/v1_covered_6e097fc9-3d25-4933-8e29-2cb65d019e7a.pdf"},{"id":61887827,"identity":"92e2618f-dc64-44a5-b092-eef70801731e","added_by":"auto","created_at":"2024-08-06 17:17:57","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":39636,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementaryexcelsheet1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4673771/v1/b470ab6289ea30b6cb792f8a.xlsx"}],"financialInterests":"No competing interests reported.","formattedTitle":"First Reported Advanced Pancreatic Cancer With Hyperprogression Treated With PD-1 Blockade combined with chemotherapy: A Case Report And Literature Review","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"discover-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"dion","sideBox":"Learn more about [Discover Oncology](https://www.springer.com/12672)","snPcode":"","submissionUrl":"","title":"Discover Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Discover Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Pancreatic cancer, combination therapy, MDM4 amplification, hyperprogressive disease, case report","lastPublishedDoi":"10.21203/rs.3.rs-4673771/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4673771/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eImmunotherapy has demonstrated significant potential in the treatment of cancer and is now recommended as a first-line therapy for small cell lung cancer and melanoma. However, a novel response pattern has been delineated, characterized by an abrupt acceleration of tumor growth subsequent to immunotherapy. These unforeseen adverse events are denoted as hyper progressive disease (HPD). The occurrence of HPD is observed not only in patients undergoing immunotherapy but also in those receiving chemotherapy, albeit with a comparatively lower frequency within the chemotherapy cohort. In the management of metastatic pancreatic cancer, the combination of chemotherapy and immunotherapy presents a promising therapeutic approach; however, there remains an unresolved question regarding the association between this combination therapy and HPD. Herein, we present a case report of a 59-year-old patient with metastatic pancreatic cancer exhibiting high PD-1/PD-L1 expression identified through next-generation sequencing data, suggesting the potential efficacy of PD-1 immunotherapy. Therefore, we administered serplulimab (a novel anti-PD-1 antibody) in combination with gemcitabine/nab-paclitaxel. The patient initially exhibited a favorable response to the combination therapy of immunotherapy and chemotherapy; however, subsequent tumor enlargement and a significant deterioration in physical condition occurred. To our knowledge, this is the first reported case of HPD in pancreatic cancer with multiple metastases treated using combination therapy. Based on this case, we propose a potential association between combination therapy and HPD in pancreatic cancer.\u003c/p\u003e","manuscriptTitle":"First Reported Advanced Pancreatic Cancer With Hyperprogression Treated With PD-1 Blockade combined with chemotherapy: A Case Report And Literature Review","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-06 17:17:52","doi":"10.21203/rs.3.rs-4673771/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-07-30T11:04:20+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-07-28T14:57:58+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-07-27T19:32:19+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"189533987921899568283501173743213772282","date":"2024-07-27T19:22:10+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"14075611993529691455119386072656753488","date":"2024-07-27T09:31:48+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-07-15T11:31:40+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-07-15T11:25:13+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-07-13T05:11:27+00:00","index":"","fulltext":""},{"type":"submitted","content":"Discover Oncology","date":"2024-07-02T11:13:58+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"discover-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"dion","sideBox":"Learn more about [Discover Oncology](https://www.springer.com/12672)","snPcode":"","submissionUrl":"","title":"Discover Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Discover Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"7b1adb2d-18f2-47d7-83c6-064c17f5fedc","owner":[],"postedDate":"August 6th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2024-10-03T04:38:41+00:00","versionOfRecord":[],"versionCreatedAt":"2024-08-06 17:17:52","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4673771","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4673771","identity":"rs-4673771","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}